Fig. 1 · Structure
Documents & Downloads
Povetacicept
BAFF/APRIL Inhibitor
Povetacicept is a dual antagonist of APRIL and BAFF, functioning as an engineered Fc fusion protein that incorporates the TACI domain. With a Kd value of 59.3 pM for human BAFF and 1.00 pM for human APRIL, Povetacicept effectively inhibits B cell activation, proliferation, differentiation, and survival, while also reducing immunoglobulin and autoantibody production. This reagent is suitable for research applications in various autoimmune conditions, including autoimmune hemolytic anemia, immune thrombocytopenia, systemic lupus erythematosus, lupus nephritis, and myasthenia gravis.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Antagonist |
| CAS Number | 2490217-42-8 |
| Applications | BAFF/APRIL Inhibitor |
| Molecular Weight | 62.61 kDa |
| Synonyms | ALPN-303 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.